Cardiovascular Endocrinology

MON-297 - Association of Admission Blood Glucose Level with Short-Term Mortality in Cardiogenic Shock Following Acute Coronary Syndrome: Systematic Review and Meta-Analysis

Monday, June 15, 2026

9:00 AM - 2:00 PM CT

Location: ENDOExpo; Poster Floor

Abstract Poster Presenter(s)

sushmitha garikipati, MD (she/her/hers)

HOLY NAME HOSPITAL
Hackensack, NJ, United States

Co-Author(s)

Nd

Natanael duarte, MD

Resident Physician
HOLY NAME MEDICAL CENTER
Maywood, New Jersey, United States
AR

Abdelrhman Refaey, MD

Resident Physician
HOLY NAME MEDICAL CENTER
Teaneck, New Jersey, United States
DS

Danna Sarmiento Dickson, MD

Resident Physician
HOLY NAME MEDICAL CENTER
hackensack, New Jersey, United States
SD

Shradha Dave, MD

Resident Physician
HOLY NAME MEDICAL CENTER
Hackensack, New Jersey, United States
BL

Bihari Lal, MD

Resident Physician
HOLY NAME MEDICAL CENTRE
Teaneck, New Jersey, United States
JA

Jahnavi Akkaldevi, MD

Resident Physician
HOLY NAME MEDICAL CENTER
Hackensack, New Jersey, United States
AV

Arlen Odalina Ventura Camilo, MD

METROPOLITAN HOSPITAL CENTER
New York, United States

Senior Author/Primary Investigator(s)

VC

Victoria Costales, MD

Internal Medicine Program Director
HOLY NAME MEDICAL CENTER
Teaneck, New Jersey, United States

Background:
Admission hyperglycemia is common in patients with cardiogenic shock following acute coronary syndrome (ACS), yet its prognostic significance remains incompletely characterized. We performed a systematic review and meta-analysis to evaluate the association between admission blood glucose and short-term mortality in ACS-related cardiogenic shock.

Methods:
This systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, Embase, and Scopus were searched from inception through January 3, 2026. Eligible studies included adults with ACS complicated by Cardiogenic shock, reported admission blood glucose, and provided mortality outcomes. Study quality was assessed using the Newcastle–Ottawa Scale. Random-effects models were used to pool risk ratios (RR) with 95% confidence intervals (CI). Statistical heterogeneity was assessed using Cochran’s Q and I² statistics.

Results:
Six studies (2007–2020) including 2,857 patients with ACS-related Cardiogenic shock met inclusion criteria; 78.2% were men, 81% had ST-segment elevation myocardial infarction, and 24.7% had diabetes. Four observational studies (n = 1,492) contributed data to the primary quantitative analysis. Patients with admission blood glucose < 7.8 mmol/L (n = 372) had significantly lower 30-day mortality compared with those with glucose ≥ 7.8 mmol/L (n = 1,120): RR 0.58, (95% CI 0.45–0.74; p = 0.006), with no observed heterogeneity (I² = 0.0%; τ² = 0; χ² = 1.76; p = 0.62). All included cohort studies achieved the maximum NOS score(9/9), reflecting low risk of bias across selection, comparability and outcome domains.

Conclusion:
Among patients with cardiogenic shock complicating ACS, an admission blood glucose level ≥ 7.8 mmol/L is associated with substantially increased short-term mortality. These findings underscore the potential value of early risk stratification based on admission glucose, but are limited by the observational design of available studies and possible publication bias. Further prospective studies are needed to determine whether targeted glycemic management improves outcomes in this high-risk population.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*